Physicochemical Properties
| Molecular Formula | C29H32CL2N4O5 |
| Molecular Weight | 587.494185447693 |
| Exact Mass | 586.174 |
| CAS # | 851333-14-7 |
| PubChem CID | 69923410 |
| Appearance | White to off-white solid powder |
| LogP | 4.1 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 16 |
| Heavy Atom Count | 40 |
| Complexity | 776 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | C(C1C=C(Cl)C=C(Cl)C=1)(CC(=O)O)NC(=O)[C@@H](NC(=O)CCCCNC1N=CC=CC=1)COCC1C=CC=CC=1 |
| InChi Key | JHJAHOCSWUTJGR-BBMPLOMVSA-N |
| InChi Code | InChI=1S/C29H32Cl2N4O5/c30-22-14-21(15-23(31)16-22)24(17-28(37)38)35-29(39)25(19-40-18-20-8-2-1-3-9-20)34-27(36)11-5-7-13-33-26-10-4-6-12-32-26/h1-4,6,8-10,12,14-16,24-25H,5,7,11,13,17-19H2,(H,32,33)(H,34,36)(H,35,39)(H,37,38)/t24?,25-/m0/s1 |
| Chemical Name | 3-(3,5-dichlorophenyl)-3-[[(2S)-3-phenylmethoxy-2-[5-(pyridin-2-ylamino)pentanoylamino]propanoyl]amino]propanoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | αvβ6 6 nM (IC50) |
| ln Vitro | EMD527040 inhibits recombinant αvβ6's binding to fibronectin at 6 nM, while αvβ3 and αvβ5 integrins (IC5050) bind at >9.5 μM[1]. The attachment of αvβ6 expressing cells (UCLAP3 cells) to fibronectin is inhibited by EMD527040 at an IC50 of 1.6 μM, while αvβ3 and αvβ5 integrins had an IC50 of >50 μM[1]. |
| ln Vivo | EMD527040 (intraperitoneal injection; 20–60 mg/kg; week 2–6) improves liver architecture and function by inducing downregulation of fibrogenic and upregulation of fibrolytic genes, attenuating bile ductular proliferation and peribiliary collagen deposition by 40–50%. EMD527040 markedly decreased the weights of the liver and spleen in Mdr2(Abcb4)-/-mice by 22% and 50%, respectively[1]. |
| Animal Protocol |
Animal/Disease Models: Male adult Wistar rats Doses: 20-60 mg/kg Route of Administration: intraperitoneal (ip)injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation) Experimental Results: Ameliorated fibrosis progression in rodents with biliary fibrosis. |
| References |
[1]. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology. 2008 Aug;135(2):660-70. [2]. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol. |
Solubility Data
| Solubility (In Vitro) | DMSO : 100 mg/mL (170.22 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7022 mL | 8.5108 mL | 17.0216 mL | |
| 5 mM | 0.3404 mL | 1.7022 mL | 3.4043 mL | |
| 10 mM | 0.1702 mL | 0.8511 mL | 1.7022 mL |